CD26 protease inhibition improves functional response of unfractionated cord blood, bone marrow, and mobilized peripheral blood cells to CXCL12/SDF-1

Experimental Hematology

Volumn 40, Issue 11, 2012, Pages 945-952

  Christopherson, Kent W ^a   Frank, Robin R ^a   Jagan, Sucheta ^a   Paganessi, Laura A ^a   Gregory, Stephanie A ^a   Fung, Henry C ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DIPROTIN A; GRANULOCYTE COLONY STIMULATING FACTOR; STROMAL CELL DERIVED FACTOR 1;

ANTIGEN EXPRESSION; ARTICLE; BONE MARROW; ENGRAFTMENT; ENZYME INHIBITION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; IMMOBILIZED CELL; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; MONONUCLEAR CELL; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; UMBILICAL CORD BLOOD;

BLOTTING, WESTERN; BONE MARROW; CELL ADHESION; CELL MOVEMENT; CHEMOKINE CXCL12; DIPEPTIDYL PEPTIDASE 4; FETAL BLOOD; FLOW CYTOMETRY; HUMANS; PROTEASE INHIBITORS;

EID: 84867403356     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2012.07.009     Document Type: Article

References (30)

1. Champlin R.E., Schmitz N., Horowitz M.M., et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). Blood 2000, 95:3702-3709.
2. Fruehauf S., Haas R., Conradt C., et al. Peripheral blood progenitor cell (PBPC) counts during steady-state hematopoiesis allow to estimate the yield of mobilized PBPC after filgrastim (R-metHuG-CSF)-supported cytotoxic chemotherapy. Blood 1995, 85:2619-2626.
3. Duhrsen U., Villeval J.L., Boyd J., Kannourakis G., Morstyn G., Metcalf D. Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 1988, 72:2074-2081.
4. Socinski M.A., Cannistra S.A., Elias A., Antman K.H., Schnipper L., Griffin J.D. Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man. Lancet 1988, 1:1194-1198.
5. Molineux G., Migdalska A., Szmitkowski M., Zsebo K., Dexter T.M. The effects on hematopoiesis of recombinant stem cell factor (ligand for c-kit) administered in vivo to mice either alone or in combination with granulocyte colony-stimulating factor. Blood 1991, 78:961-966.
6. Brasel K., McKenna H.J., Morrissey P.J., et al. Hematologic effects of flt3 ligand in vivo in mice. Blood 1996, 88:2004-2012.
7. Orazi A., Cattoretti G., Schiro R., et al. Recombinant human interleukin-3 and recombinant human granulocyte-macrophage colony-stimulating factor administered in vivo after high-dose cyclophosphamide cancer chemotherapy: effect on hematopoiesis and microenvironment in human bone marrow. Blood 1992, 79:2610-2619.
8. Bensinger W., Appelbaum F., Rowley S., et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 1995, 13:2547-2555.
9. Flomenberg N., Devine S.M., Dipersio J.F., et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005, 106:1867-1874.
10. Harris D.T. Cord blood transplantation: implications for graft vs. host disease and graft vs. leukemia. Blood Cells 1994, 20:560-564. discussion 564-565.
11. Barker J.N., Weisdorf D.J., DeFor T.E., et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 2005, 105:1343-1347.
12. Xu R., Reems J.A. Umbilical cord blood progeny cells that retain a CD34+ phenotype after ex vivo expansion have less engraftment potential than unexpanded CD34+ cells. Transfusion 2001, 41:213-218.
13. Oppenheim J.J. Overview of chemokines. Adv Exp Med Biol 1993, 351:183-186.
14. Christopherson K., Hromas R. Chemokine regulation of normal and pathologic immune responses. Stem Cells 2001, 19:388-396.
15. Zou Y.R., Kottmann A.H., Kuroda M., Taniuchi I., Littman D.R. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 1998, 393:595-599.
16. Peled A., Kollet O., Ponomaryov T., et al. The chemokine SDF-1 activates the integrins LFA-1, VLA-4, and VLA-5 on immature human CD34(+) cells: role in transendothelial/stromal migration and engraftment of NOD/SCID mice. Blood 2000, 95:3289-3296.
17. Bongers J., Lambros T., Ahmad M., Heimer E.P. Kinetics of dipeptidyl peptidase IV proteolysis of growth hormone-releasing factor and analogs. Biochim Biophys Acta 1992, 1122:147-153.
18. Durinx C., Lambeir A.M., Bosmans E., et al. Molecular characterization of dipeptidyl peptidase activity in serum: soluble CD26/dipeptidyl peptidase IV is responsible for the release of X-Pro dipeptides. Eur J Biochem 2000, 267:5608-5613.
19. Lambeir A.M., Proost P., Durinx C., et al. Kinetic investigation of chemokine truncation by CD26/dipeptidyl peptidase IV reveals a striking selectivity within the chemokine family. J Biol Chem 2001, 276:29839-29845.
20. Rasmussen H.B., Branner S., Wiberg F.C., Wagtmann N. Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog. Nat Struct Biol 2003, 10:19-25.
21. Christopherson K.W., Hangoc G., Broxmeyer H.E. Cell surface peptidase CD26/dipeptidylpeptidase IV regulates CXCL12/stromal cell-derived factor-1 alpha-mediated chemotaxis of human cord blood CD34+ progenitor cells. J Immunol 2002, 169:7000-7008.
22. Christopherson K.W., Paganessi L.A., Napier S., Porecha N.K. CD26 inhibition on CD34+ or lineage- human umbilical cord blood donor hematopoietic stem cells/hematopoietic progenitor cells improves long-term engraftment into NOD/SCID/Beta2null immunodeficient mice. Stem Cells Dev 2007, 16:355-360.
23. Kawai T., Choi U., Liu P.C., Whiting-Theobald N.L., Linton G.F., Malech H.L. Diprotin A infusion into nonobese diabetic/severe combined immunodeficiency mice markedly enhances engraftment of human mobilized CD34+ peripheral blood cells. Stem Cells Dev 2007, 16:361-370.
24. Christopherson K.W., Cooper S., Broxmeyer H.E. Cell surface peptidase CD26/DPPIV mediates G-CSF mobilization of mouse progenitor cells. Blood 2003, 101:4680-4686.
25. Aytac U., Claret F.X., Ho L., et al. Expression of CD26 and its associated dipeptidyl peptidase IV enzyme activity enhances sensitivity to doxorubicin-induced cell cycle arrest at the G(2)/M checkpoint. Cancer Res 2001, 61:7204-7210.
26. Yamada K., Hayashi M., Du W., et al. Localization of CD26/DPPIV in nucleus and its nuclear translocation enhanced by anti-CD26 monoclonal antibody with anti-tumor effect. Cancer Cell Int 2009, 9:17.
27. Broxmeyer H.E., Orschell C.M., Clapp D.W., et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med 2005, 201:1307-1318.
28. Bonig H., Chudziak D., Priestley G., Papayannopoulou T. Insights into the biology of mobilized hematopoietic stem/progenitor cells through innovative treatment schedules of the CXCR4 antagonist AMD3100. Exp Hematol 2009, 37:402-415.e401.
29. Rettig M.P., Ramirez P., Nervi B., DiPersio J.F. CXCR4 and mobilization of hematopoietic precursors. Methods Enzymol 2009, 460:57-90.
30. Paganessi L.A., Walker A.L., Tan L.L., et al. Effective mobilization of hematopoietic progenitor cells in G-CSF mobilization defective CD26-/- mice through AMD3100-induced disruption of the CXCL12-CXCR4 axis. Exp Hematol 2011, 39:384-390.